Table 5.

Breast cancer–specific MRRs comparing older with younger age at diagnosis, stratified by tumor subtype, NCICC, and guideline-concordant treatment, California, 2005–2014

Younger (18–49), number of deathsOlder (50+), number of deathsMRR (95% CI)a Older vs. younger (referent)MRR (95% CI)b Older vs. younger (referent)
Tumor subtype
 HR+/HER28202,7811.00 (0.93–1.08)1.24 (1.14–1.35)
 HR+/HER2+2365981.34 (1.15–1.56)1.38 (1.17–1.62)
 HR/HER2+2144760.97 (0.82–1.14)0.94 (0.79–1.12)
 Triple negative7381,5180.95 (0.87–1.04)1.01 (0.92–1.11)
 Unclassified2288601.16 (1.00–1.34)1.31 (1.12–1.53)
 No1,9015,7840.97 (0.92–1.02)1.21 (1.15–1.28)
 Yes3354490.74 (0.64–0.85)0.86 (0.73–1.01)
Guideline-concordant treatment
 Yes1,4092,8791.04 (0.94–1.10)1.06 (0.99–1.14)
 No2306571.18 (1.02–1.37)1.20 (1.02–1.41)
 Not available5902,6831.21 (1.11–1.33)1.34 (1.22–1.47)
  • aAdjusted for year of diagnosis.

  • bStratified by AJCC stage and adjusted for year of diagnosis, marital status, race/ethnicity, insurance status, nSES, lymph node involvement, tumor subtype (in models not stratified by this), tumor size, tumor grade, tumor histology, guideline-concordant treatment (in models not stratified by this), NCICC (in models not stratified by this), and clustering by block group.